Calithera Biosciences, Inc.
CALA
Price:
$0.05
Market Cap:
$243.63K
Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule compounds for tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. The company offers INCB001158, an orally bioavailable arginase inhibitor of arginase that is in Phase 1/2 clinical trial for the treatment of hematology and oncology. It is developing CB-280, an oral arginase inhibitor that has completed Phase 1b clinical trial for the treatment of cystic fibrosis and chronic airway infection; and ATG-037, an orally-bioavailable small molecule inhibitor of CD73, as well as CB-668, an orally administered inhibitor of the...[Read more]
Industry
Biotechnology
IPO Date
2014-10-02
Stock Exchange
NASDAQ
Ticker
CALA
The ROE as of September 2024 (TTM) for Calithera Biosciences, Inc. (CALA) is 8.01%
According to Calithera Biosciences, Inc.’s latest financial reports and current stock price. The company's current ROE is 8.01%. This represents a change of -93.61% compared to the average of 125.38% of the last 4 quarters.
Calithera Biosciences, Inc. (CALA) Historical ROE (quarterly & annually)
How has CALA ROE performed in the past?
The mean historical ROE of Calithera Biosciences, Inc. over the last ten years is -1.77%. The current 8.01% ROE has changed -552.26% with respect to the historical average. Over the past ten years (40 quarters), CALA's ROE was at its highest in in the March 2022 quarter at 441.45%. The ROE was at its lowest in in the September 2022 quarter at -38.19%.
Average
-1.77%
Median
24.88%
Minimum
-92.52%
Maximum
59.47%
Calithera Biosciences, Inc. (CALA) ROE by Quarter and Year
Discovering the peaks and valleys of Calithera Biosciences, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 67.47%
Maximum Annual ROE = 59.47%
Minimum Annual Increase = -374.93%
Minimum Annual ROE = -92.52%
| Year | ROE | Change |
|---|---|---|
| 2022 | -92.52% | -374.93% |
| 2021 | 33.65% | 43.02% |
| 2020 | 23.53% | -22.04% |
| 2019 | 30.18% | 15.02% |
| 2018 | 26.24% | -241.73% |
| 2017 | -18.51% | -75.69% |
| 2016 | -76.15% | 67.47% |
| 2015 | -45.47% | -208.60% |
| 2014 | 41.87% | -29.59% |
| 2013 | 59.47% | -36.09% |
Calithera Biosciences, Inc. (CALA) Average ROE
How has CALA ROE performed in the past?
The current ROE of Calithera Biosciences, Inc. (CALA) is greater than its 3-year, less than than its 5-year, and greater than its 10-year historical averages
3-year avg
-11.78%
5-year avg
4.22%
10-year avg
-1.77%
Calithera Biosciences, Inc. (CALA) ROE vs. Peers
How is CALA’s ROE compared to its peers?
Calithera Biosciences, Inc.’s ROE is less than Abeona Therapeutics Inc. (0%), greater than Affimed N.V. (-207.85%), greater than Checkpoint Therapeutics, Inc. (-155.57%), less than Adaptimmune Therapeutics plc (292.43%), greater than Mereo BioPharma Group plc (-117.47%), greater than Pieris Pharmaceuticals, Inc. (-63.39%), greater than PDS Biotechnology Corporation (-97.28%), greater than Leap Therapeutics, Inc. (-137.06%), greater than Kodiak Sciences Inc. (-98.01%), greater than Galmed Pharmaceuticals Ltd. (-77.23%), greater than Adverum Biotechnologies, Inc. (-43.60%), greater than Ardelyx, Inc. (-74.45%), greater than Zura Bio Limited (-39.73%), greater than Hepion Pharmaceuticals, Inc. (-35.45%), greater than AVROBIO, Inc. (-328.66%), less than Verastem, Inc. (29.68%), greater than null (-133.02%),
| Company | ROE | Market cap |
|---|---|---|
| 0% | $236.06M | |
| -207.85% | $61.21M | |
| -155.57% | $109.02M | |
| 292.43% | $265.93M | |
| -117.47% | $739.24M | |
| -63.39% | $21.34M | |
| -97.28% | $113.04M | |
| -137.06% | $110.20M | |
| -98.01% | $139.96M | |
| -77.23% | $1.14M | |
| -43.60% | $145.40M | |
| -74.45% | $1.39B | |
| -39.73% | $263.39M | |
| -35.45% | $3.91M | |
| -328.66% | $5.24M | |
| 29.68% | $109.06M | |
| -133.02% | $0 |
Build a custom stock screener for Calithera Biosciences, Inc. (CALA) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Calithera Biosciences, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Calithera Biosciences, Inc. (CALA) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Calithera Biosciences, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Calithera Biosciences, Inc.'s ROE?
How is the ROE calculated for Calithera Biosciences, Inc. (CALA)?
What is the highest ROE for Calithera Biosciences, Inc. (CALA)?
What is the 3-year average ROE for Calithera Biosciences, Inc. (CALA)?
What is the 5-year average ROE for Calithera Biosciences, Inc. (CALA)?
How does the current ROE for Calithera Biosciences, Inc. (CALA) compare to its historical average?